04:27 AM EDT, 06/17/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 study of its experimental drug, Calquence, in combination with bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with standard-of-care in certain patients with mantle cell lymphoma, a rare type of blood cancer.

The company said the combination therapy reduced the risk of disease progression or death by 27% compared with standard-of-care chemoimmunotherapy.

Additionally, the combination treatment also showed a favorable trend in overall survival.

Price: 79.55, Change: -0.04, Percent Change: -0.05